🇺🇸 FDA
Patent

US 12180192

Modulators of THR-β and methods of use thereof

granted A61PA61P5/14

Quick answer

US patent 12180192 (Modulators of THR-β and methods of use thereof) held by Aligos Therapeutics, Inc. expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61P, A61P5/14